SPARK THERAPEUTICS, INC.: 10-Q filed 2015-11-06
What SPARK THERAPEUTICS, INC. reported in its quarterly report filed 2015-11-06 (fiscal Q3 2015): 23 published measures, 62 facts as tagged in accession 0001628280-15-008448.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-11-06
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001628280-15-008448 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SPARK THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 228,909,929 | USD | |
| At 2014-12-31 | 90,445,851 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 37,210,423 | USD | |
| At 2014-12-31 | 35,240,131 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 191,699,506 | USD | |
| At 2014-12-31 | 55,205,720 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 212,159,198 | USD | |
| At 2014-12-31 | 74,566,963 | USD | |
| At 2014-09-30 | 67,272,601 | USD | |
| At 2013-12-31 | 0 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -16,900,560 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -40,970,909 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -6,756,924 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -15,309,164 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 3,077,736 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 4,963,836 | USD | 273 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 1,302,789 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 4,865,885 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 0 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 20,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -122,573,515 | USD | |
| At 2014-12-31 | -81,602,606 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 14,194,325 | USD | |
| At 2014-12-31 | 12,674,372 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 8,479,278 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 2,227,698 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -16,955,341 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -41,088,328 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -6,758,933 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -15,311,271 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 214,297,958 | USD | |
| At 2014-12-31 | 77,363,268 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 18,615,583 | USD | |
| At 2014-12-31 | 15,854,228 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 6,227,978 | USD | |
| At 2014-12-31 | 2,676,697 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 18,258,130 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 45,954,213 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 6,758,933 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 15,331,271 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 11,796,455 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 29,474,535 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 4,652,056 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 10,169,362 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 24,569,919 | shares | |
| At 2014-12-31 | 6,290,317 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 314,248,451 | USD | |
| At 2014-12-31 | 54,364,833 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 417,646 | USD | |
| At 2014-12-31 | 408,211 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 6,085,079 | USD | |
| At 2014-12-31 | 3,163,154 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -16,900,560 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -41,605,703 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -6,756,924 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -15,309,164 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 6,461,675 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 16,479,678 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 2,106,877 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 5,161,909 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 1,245,569 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 15,849 | USD | 273 |
Inspect the source
- Entity
- SPARK THERAPEUTICS, INC. / CIK 0001609351
- Captured
- SEC response SHA-256
7fe632d855eed754412cbe5e778ed6aaccb00c4b0d20a4d3c728df0af3a78c9c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001609351.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))